股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 福森藥業有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01652 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,000,000,000 | HKD | | 0.01 | HKD | | 20,000,000 | 本月底法定/註 ...

Core Viewpoint - Fosen Pharmaceutical (01652.HK) has received approval from the National Medical Products Administration of China for its potassium hydrogen phosphate injection, branded as "Shanweixi," which is intended as a phosphate supplement [1] Group 1: Product Details - The potassium hydrogen phosphate injection is primarily used for parenteral nutrition when oral or enteral nutrition is not feasible, insufficient, or contraindicated [1] - It is also indicated for adults and children suffering from hypophosphatemia [1] - The product is classified as a Category B item under the National Medical Insurance Bureau, highlighting its safety, rapid absorption, dual phosphate supplementation, and alignment with multiple clinical guidelines [1]

Core Viewpoint - Fosun Pharma's subsidiary has received approval from the National Medical Products Administration of China for the "Compound Potassium Hydrogen Phosphate Injection," which is intended as a phosphate supplement for patients unable to receive oral or enteral nutrition [1][2]. Group 1: Product Details - The "Compound Potassium Hydrogen Phosphate Injection" is primarily used for patients with hypophosphatemia and those requiring parenteral nutrition supplementation [1]. - This new generation phosphate-potassium compound formulation aims to quickly correct phosphate deficiency while stabilizing cell membrane potential through potassium supplementation, thereby preventing risks associated with hypophosphatemia such as rhabdomyolysis and arrhythmias [1]. - The product is classified as a Category B item by the National Healthcare Security Administration, highlighting its high safety profile, rapid absorption, dual phosphate-potassium supplementation, and alignment with multiple clinical guidelines [1]. Group 2: Market Potential - According to data from Minai Network, the domestic sales of the "Compound Potassium Hydrogen Phosphate Injection" are projected to be 343 million yuan in 2023 and 413 million yuan in 2024 [1]. - The launch of this product enhances the company's portfolio in the nutritional supplement treatment sector, providing more treatment options for adults and children suffering from hypophosphatemia and those needing parenteral phosphate supplementation [2].

Core Viewpoint - Fosen Pharmaceutical's subsidiary has received approval from the National Medical Products Administration of China for its "Compound Potassium Hydrogen Phosphate Injection," which is intended as a phosphate supplement for patients unable to receive oral or enteral nutrition [1][2] Group 1: Product Details - The "Compound Potassium Hydrogen Phosphate Injection" is primarily used for patients with hypophosphatemia and those requiring parenteral nutrition supplementation [1] - The product is a new generation phosphate-potassium compound formulation that quickly corrects phosphate deficiency while stabilizing cell membrane potential through potassium supplementation [1] - The domestic sales forecast for the injection is projected to be CNY 343 million in 2023 and CNY 413 million in 2024 [1] Group 2: Market Position and Benefits - The injection is classified as a Category B product by the National Healthcare Security Administration, highlighting its safety, rapid absorption, and dual phosphate-potassium supplementation [1] - The formulation is consistent with the reference original research product, ensuring quality control that meets or exceeds the original product standards [1] - The product offers significant risk-benefit advantages in improving laboratory results and clinical symptoms for both adult and pediatric patients with hypophosphatemia [1]

"复合磷酸氢钾注射液"是国家医疗保障局医保乙类品种，具有安全性高、吸收起效快、磷酸钾双补、多 指南共识等特点。我公司开发的"复合磷酸氢钾注射液"其处方与原研参比制剂一致，并严格控制产品品 质，确保其品质优於或与原研制剂产品一致，保障患者用药安全。"复合磷酸氢钾注射液"在治疗低磷血 症及需以肠外营养补充磷酸的患者，改善成人和儿童患者的实验室检查结果和临床症状等方面提供了非 常有利的风险获益比。 "复合磷酸氢钾注射液"是集团又一款重要产品，进一步丰富了集团在营养补充剂治疗领域的产品管线。 该产品的上市为患有低磷血症的成人和儿童、及需以肠外营养补磷酸的患者提供更多的治疗选择。 格隆汇12月29日丨福森药业(01652.HK)宣布，集团的全资附属公司嘉亨(珠海横琴)医药科技有限公司研 发的"复合磷酸氢钾注射液"(商标：膳维喜)，上市申请已获得中国国家药品监督管理局批准，批准作为 磷酸补充剂。 "复合磷酸氢钾注射液"主要用于治疗当口服或肠内营养无法进行、不足或有禁忌时，以肠外营养补充， 或患有低磷血症的成人和儿童患者。作为新一代磷钾复合制剂，通过科学配比磷酸氢二钾与磷酸二氢 钾，可快速纠正磷缺乏，同时钾元素的同步补充可 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 福森藥業有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事會（「董事會」） 欣然宣佈，本集團之全資附屬公司嘉亨（ 珠海橫琴 ）醫藥科技有限公司研發的「複 合 磷 酸 氫 鉀 注 射 液」（ 商 標 ： 膳 維 喜 ）， 上 市 申 請 已 獲 得 中 國 國 家 藥 品 監 督 管 理 局 批准，批准作為磷酸補充劑。 「複合磷酸氫鉀注射液」主要用於治療當口服或腸內營養無法進行、不足或有禁忌 時，以腸外營養補充，或患有低磷血症的成人和兒童患者。作為新一代磷鉀複合 製劑，通過科學配比磷酸氫二鉀與磷酸二氫鉀，可快速糾正磷缺乏，同時鉀元素 的 同 步 補 充 可 穩 定 細 胞 ...

Core Viewpoint - Fosun Pharma (01652) announced the resignation of KPMG as its auditor due to a failure to reach an agreement on the proposed audit fees for the fiscal year ending December 31, 2025 [1] Group 1 - The resignation of KPMG will be effective from December 24, 2025 [1] - Zhongzheng Tianheng Accounting Firm has been appointed as the new auditor to fill the vacancy left by KPMG, effective from December 24, 2025 [1] - The term of the new auditor will last until the conclusion of the next annual general meeting of the company [1]

Group 1 - The company, Fosen Pharmaceutical (01652), announced that it has terminated its auditor, KPMG, due to a failure to reach an agreement on the proposed audit fees for the fiscal year ending December 31, 2025 [1] - Zhongzheng Tianheng Accounting Firm has been appointed as the new auditor to fill the vacancy left by KPMG, effective from December 24, 2025, until the conclusion of the next annual general meeting [1]

Group 1 - The core point of the article is that Fosen Pharmaceutical (01652.HK) announced the resignation of KPMG as the company's auditor due to a failure to reach an agreement on the proposed audit fees for the financial year ending December 31, 2025 [1] - The board has appointed Zhongzheng Tianheng as the new auditor to fill the vacancy left by KPMG, effective from December 24, 2025, until the conclusion of the next annual general meeting [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本公司董事（「董事」）會（「董事會」）宣佈，由於董事會與畢馬威會計師事務所（「畢 馬威」）未能就本集團截至2025年12月31日止財政年度綜合財務報表的建議審核費 用達成共識，故畢馬威已辭任本公司核數師，自2025年12月24日起生效。 本公司根據開曼群島法律註冊成立，據董事會所知，開曼群島法律並無規定退任 核數師確認是否有任何情況因其退任而致使其認為應提請本公司股東（「股東」）垂 注。因此，畢馬威並無出具有關確認函。董事會及本公司審核委員會（「審核委員 會」）確認，除上文披露者外，畢馬威與本公司之間概無意見分歧，亦無其他有關 上述核數師辭任的事宜或狀況須提請股東垂注。 Fusen Pharmaceutical Company Limited 福 森 藥 業 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1652） 核數師 ...